[
  {
    "ts": null,
    "headline": "Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
    "summary": "LONDON, July 14, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine.",
    "url": "https://finnhub.io/api/news?id=1db97c145e7f2c5efd47aa79e3366b4fb6d4c470e4369f098922a91a47c307f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752534060,
      "headline": "Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
      "id": 135933942,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "LONDON, July 14, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine.",
      "url": "https://finnhub.io/api/news?id=1db97c145e7f2c5efd47aa79e3366b4fb6d4c470e4369f098922a91a47c307f7"
    }
  },
  {
    "ts": null,
    "headline": "Vertex announces broad reimbursement agreement with NHS England for Alyftrek for the treatment of cystic fibrosis",
    "summary": "Vertex Pharmaceuticals Inc: Vertex announces broad reimbursement agreement with NHS England for Alyftrek® , an innovative once-daily CFTR modulator for the treatment of cystic fibrosis...",
    "url": "https://finnhub.io/api/news?id=7aa9f852c79558619ad553d2a8bf9b3917c12c41307293e80dd31c08ad53e709",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752519909,
      "headline": "Vertex announces broad reimbursement agreement with NHS England for Alyftrek for the treatment of cystic fibrosis",
      "id": 135931488,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex Pharmaceuticals Inc: Vertex announces broad reimbursement agreement with NHS England for Alyftrek® , an innovative once-daily CFTR modulator for the treatment of cystic fibrosis...",
      "url": "https://finnhub.io/api/news?id=7aa9f852c79558619ad553d2a8bf9b3917c12c41307293e80dd31c08ad53e709"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain",
    "summary": "BOSTON, July 14, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain, as a groundbreaking health care technology.",
    "url": "https://finnhub.io/api/news?id=583be07f9740c717be1c41d56ef75b3c9b32c406910e90b9de3e473db11fe339",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752496200,
      "headline": "Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain",
      "id": 135926701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, July 14, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain, as a groundbreaking health care technology.",
      "url": "https://finnhub.io/api/news?id=583be07f9740c717be1c41d56ef75b3c9b32c406910e90b9de3e473db11fe339"
    }
  },
  {
    "ts": null,
    "headline": "My 3 Top Stocks to Buy in a Market That's Highly Volatile (Again)",
    "summary": "Dominion Energy is the kind of stable utility stock that's great to own during turbulent markets.  Enbridge has a lower risk than ever before with its midstream and natural gas utility businesses.  Vertex Pharmaceuticals boasts a strong cystic fibrosis franchise along with exciting new products and pipeline candidates.",
    "url": "https://finnhub.io/api/news?id=14ed02ab97c70187bf51e6de929c4a4c890462f9c7d3ed20c9d6ab69f134a818",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752482640,
      "headline": "My 3 Top Stocks to Buy in a Market That's Highly Volatile (Again)",
      "id": 135921114,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Dominion Energy is the kind of stable utility stock that's great to own during turbulent markets.  Enbridge has a lower risk than ever before with its midstream and natural gas utility businesses.  Vertex Pharmaceuticals boasts a strong cystic fibrosis franchise along with exciting new products and pipeline candidates.",
      "url": "https://finnhub.io/api/news?id=14ed02ab97c70187bf51e6de929c4a4c890462f9c7d3ed20c9d6ab69f134a818"
    }
  }
]